A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia

Abstract Introduction Sodium selenate increases tau dephosphorylation through protein phosphatase 2 activation. Here we report an open‐label Phase 1b study of sodium selenate as a disease‐modifying treatment for behavioral variant frontotemporal dementia (bvFTD). Methods Twelve participants with bvF...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao‐Xin Li, Stuart McDonald, William T. O'Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis, Terence J. O'Brien
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2022-01-01
Series:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Assuntos:	anti‐tau treatment behavioral variant frontotemporal dementia (bvFTD) clinical trial fluid biomarkers frontotemporal lobar degeneration (FTLD) magnetic resonance imaging (MRI)
Acceso en liña:	https://doi.org/10.1002/trc2.12299
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!